Status:
COMPLETED
Safety, Tolerability, and Pharmacokinetics of AZD7268 After Single Ascending Oral Doses in Healthy Subjects
Lead Sponsor:
AstraZeneca
Conditions:
Healthy Volunteer
Eligibility:
All Genders
18-45 years
Phase:
PHASE1
Brief Summary
Single Ascending Dose Study
Eligibility Criteria
Inclusion
- Provision of Informed Consent
- Healthy male subjects and female subjects (of non-child bearing potential) with suitable veins for cannulation or repeated venipuncture
Exclusion
- Inability to understand or cooperate with given information
- Positive human immune deficiency virus (HIV), Hepatitis B, or Hepatitis C test
- Clinically relevant abnormalities in physical examinations, vital signs, ECG, clinical chemistry, hematology, and urinanalysis
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT00796965
Start Date
December 1 2008
End Date
March 1 2009
Last Update
August 19 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Philadelphia, Pennsylvania, United States